Econlex supports Startups development in the Biotech Industry

Econlex Development Strategies has developed an alliance with Iasotek LLC, a biotech startup company spin-off of Arizona State University, currently developing a new model for prototypes for dianosing dengue.

Iasotek has developed an innovative prototype that can perform complex laboratory assays, and do so with such simplicity that these tests can be carried out in the most remote regions of the world. Iasotek's research is based on the premise that microfluidics—the manipulation of small amounts of fluids—and nanoparticles can be successfully leveraged to produce a functional low-cost diagnostic device in extreme resource-limited settings. 

Their device, known as Bioxplor, requires only a tiny finger prick of blood, effective even for a newborn, and gives—in less than 15 minutes—quantitative objective results that are not subject to user interpretation. This new technology significantly reduces the time between testing patients and treating them, providing medical workers in the field results that are much easier to read at a much lower cost. New low-cost diagnostics like the Bioxplor could revolutionize medical care around the world.

Currently, Iasotek is developing a disposable credit card-sized device that can produce blood-based diagnostic results in minutes. The goal is to make a large class of diagnostic tests accessible to patients in any setting in the world, rather than forcing them to go to a clinic to draw blood and then wait days for their results.

For more information visit Iasotek's website